Terms: = Prostate cancer AND DNMT3A, Q9Y6K1, 1788, ENSG00000119772, DNMT3A2, M_HsaIIIA AND Treatment
19 results:
1. Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
Rautajoki KJ; Jaatinen S; Hartewig A; Tiihonen AM; Annala M; Salonen I; Valkonen M; Simola V; Vuorinen EM; Kivinen A; Rauhala MJ; Nurminen R; Maass KK; Lahtela SL; Jukkola A; Yli-Harja O; Helén P; Pajtler KW; Ruusuvuori P; Haapasalo J; Zhang W; Haapasalo H; Nykter M
Acta Neuropathol Commun; 2023 Nov; 11(1):176. PubMed ID: 37932833
[TBL] [Abstract] [Full Text] [Related]
2. Regulation of SPDEF expression by DNA methylation in advanced prostate cancer.
Vatanmakanian M; Steffan JJ; Koul S; Ochoa AC; Chaturvedi LS; Koul HK
Front Endocrinol (Lausanne); 2023; 14():1156120. PubMed ID: 37900138
[TBL] [Abstract] [Full Text] [Related]
3. Mechanistic Insights into Harmine-Mediated Inhibition of Human DNA Methyltransferases and prostate cancer Cell Growth.
Cho CC; Lin CJ; Huang HH; Yang WZ; Fei CY; Lin HY; Lee MS; Yuan HS
ACS Chem Biol; 2023 Jun; 18(6):1335-1350. PubMed ID: 37188336
[TBL] [Abstract] [Full Text] [Related]
4. Targeting DNMTs to Overcome Enzalutamide Resistance in prostate cancer.
Farah E; Zhang Z; Utturkar SM; Liu J; Ratliff TL; Liu X
Mol Cancer Ther; 2022 Jan; 21(1):193-205. PubMed ID: 34728570
[TBL] [Abstract] [Full Text] [Related]
5. Out-of-pocket costs for commercially insured patients with localized prostate cancer.
Wallis CJD; Joyce DD; Klaassen Z; Luckenbaugh AN; Laviana AA; Penson D; Dusetzina SB; Barocas DA
Urol Oncol; 2021 Dec; 39(12):797-805. PubMed ID: 34600803
[TBL] [Abstract] [Full Text] [Related]
6. Co-Targeting Plk1 and dnmt3a in Advanced prostate cancer.
Zhang Z; Cheng L; Zhang Q; Kong Y; He D; Li K; Rea M; Wang J; Wang R; Liu J; Li Z; Yuan C; Liu E; Fondufe-Mittendorf YN; Li L; Han T; Wang C; Liu X
Adv Sci (Weinh); 2021 Jul; 8(13):e2101458. PubMed ID: 34051063
[TBL] [Abstract] [Full Text] [Related]
7. Expression of UDP Glucuronosyltransferases
Shafiee-Kermani F; Carney ST; Jima D; Utin UC; Farrar LB; Oputa MO; Hines MR; Kinyamu HK; Trotter KW; Archer TK; Hoyo C; Koller BH; Freedland SJ; Grant DJ
Epigenetics; 2021 Mar; 16(3):289-299. PubMed ID: 32660355
[TBL] [Abstract] [Full Text] [Related]
8. Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells.
Zwergel C; Schnekenburger M; Sarno F; Battistelli C; Manara MC; Stazi G; Mazzone R; Fioravanti R; Gros C; Ausseil F; Florean C; Nebbioso A; Strippoli R; Ushijima T; Scotlandi K; Tripodi M; Arimondo PB; Altucci L; Diederich M; Mai A; Valente S
Clin Epigenetics; 2019 May; 11(1):68. PubMed ID: 31060628
[TBL] [Abstract] [Full Text] [Related]
9. Epigenetic reactivation of RASSF1A by phenethyl isothiocyanate (PEITC) and promotion of apoptosis in LNCaP cells.
Boyanapalli SS; Li W; Fuentes F; Guo Y; Ramirez CN; Gonzalez XP; Pung D; Kong AN
Pharmacol Res; 2016 Dec; 114():175-184. PubMed ID: 27818231
[TBL] [Abstract] [Full Text] [Related]
10. Regulation of miR-200c and miR-141 by Methylation in prostate cancer.
Lynch SM; O'Neill KM; McKenna MM; Walsh CP; McKenna DJ
Prostate; 2016 Sep; 76(13):1146-59. PubMed ID: 27198154
[TBL] [Abstract] [Full Text] [Related]
11. Epigenetics Reactivation of Nrf2 in prostate TRAMP C1 Cells by Curcumin Analogue FN1.
Li W; Pung D; Su ZY; Guo Y; Zhang C; Yang AY; Zheng X; Du ZY; Zhang K; Kong AN
Chem Res Toxicol; 2016 Apr; 29(4):694-703. PubMed ID: 26991801
[TBL] [Abstract] [Full Text] [Related]
12. Effect of patient navigation on satisfaction with cancer-related care.
Wells KJ; Winters PC; Jean-Pierre P; Warren-Mears V; Post D; Van Duyn MA; Fiscella K; Darnell J; Freund KM;
Support Care Cancer; 2016 Apr; 24(4):1729-53. PubMed ID: 26438146
[TBL] [Abstract] [Full Text] [Related]
13. ERG induces a mesenchymal-like state associated with chemoresistance in leukemia cells.
Mochmann LH; Neumann M; von der Heide EK; Nowak V; Kühl AA; Ortiz-Tanchez J; Bock J; Hofmann WK; Baldus CD
Oncotarget; 2014 Jan; 5(2):351-62. PubMed ID: 24504051
[TBL] [Abstract] [Full Text] [Related]
14. Mahanine restores RASSF1A expression by down-regulating DNMT1 and DNMT3B in prostate cancer cells.
Agarwal S; Amin KS; Jagadeesh S; Baishay G; Rao PG; Barua NC; Bhattacharya S; Banerjee PP
Mol Cancer; 2013 Aug; 12(1):99. PubMed ID: 24001151
[TBL] [Abstract] [Full Text] [Related]
15. Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells.
Gravina GL; Ranieri G; Muzi P; Marampon F; Mancini A; Di Pasquale B; Di Clemente L; Dolo V; D'Alessandro AM; Festuccia C
Oncol Rep; 2013 Mar; 29(3):1189-95. PubMed ID: 23254386
[TBL] [Abstract] [Full Text] [Related]
16. Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models.
Gravina GL; Marampon F; Piccolella M; Motta M; Ventura L; Pomante R; Popov VM; Zani BM; Pestell RG; Tombolini V; Jannini EA; Festuccia C
Endocrinology; 2011 Dec; 152(12):4550-61. PubMed ID: 21990314
[TBL] [Abstract] [Full Text] [Related]
17. Epigenetic CpG demethylation of the promoter and reactivation of the expression of Neurog1 by curcumin in prostate LNCaP cells.
Shu L; Khor TO; Lee JH; Boyanapalli SS; Huang Y; Wu TY; Saw CL; Cheung KL; Kong AN
AAPS J; 2011 Dec; 13(4):606-14. PubMed ID: 21938566
[TBL] [Abstract] [Full Text] [Related]
18. Modulation of E-cadherin expression by K-Ras; involvement of DNA methyltransferase-3b.
Kwon O; Jeong SJ; Kim SO; He L; Lee HG; Jang KL; Osada H; Jung M; Kim BY; Ahn JS
Carcinogenesis; 2010 Jul; 31(7):1194-201. PubMed ID: 20375073
[TBL] [Abstract] [Full Text] [Related]
19. Clinical assessment of three-dimensional ultrasound prostate localization for external beam radiotherapy.
Orton NP; Jaradat HA; Tomé WA
Med Phys; 2006 Dec; 33(12):4710-7. PubMed ID: 17278823
[TBL] [Abstract] [Full Text] [Related]
